Pfizer expects growth after 2028 on obesity drug pipeline
Pfizer beat first-quarter estimates with 14.45 billion dollars in revenue. The firm expects obesity and cancer drugs to drive stronger growth starting in 2029.
Xurve View
Insights:
Xurve View
PFIZER INC forecasts high-single-digit growth from 2029 after beating first-quarter revenue estimates with $14.45 billion on Tuesday morning. The drugmaker is pivoting toward obesity and cancer treatments to offset a 59% drop in COVID-19 vaccine sales. Investors are weighing near-term patent expirations against a pipeline that won't deliver major obesity results until after 2028.
